EP0522081A4 - Inhibition of disease associated with immunodeficiency virus infection - Google Patents

Inhibition of disease associated with immunodeficiency virus infection

Info

Publication number
EP0522081A4
EP0522081A4 EP19910908056 EP91908056A EP0522081A4 EP 0522081 A4 EP0522081 A4 EP 0522081A4 EP 19910908056 EP19910908056 EP 19910908056 EP 91908056 A EP91908056 A EP 91908056A EP 0522081 A4 EP0522081 A4 EP 0522081A4
Authority
EP
European Patent Office
Prior art keywords
inhibition
immunodeficiency virus
virus infection
disease associated
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19910908056
Other languages
English (en)
Other versions
EP0522081A1 (en
Inventor
Christine Marie Debouck
David Alan 4124 Rittenhouse Lane Brake
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SmithKline Beecham Corp
Original Assignee
SmithKline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by SmithKline Beecham Corp filed Critical SmithKline Beecham Corp
Publication of EP0522081A1 publication Critical patent/EP0522081A1/en
Publication of EP0522081A4 publication Critical patent/EP0522081A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16311—Human Immunodeficiency Virus, HIV concerning HIV regulatory proteins
    • C12N2740/16322—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP19910908056 1990-03-30 1991-03-29 Inhibition of disease associated with immunodeficiency virus infection Withdrawn EP0522081A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US50200690A 1990-03-30 1990-03-30
US502006 1990-03-30

Publications (2)

Publication Number Publication Date
EP0522081A1 EP0522081A1 (en) 1993-01-13
EP0522081A4 true EP0522081A4 (en) 1993-06-16

Family

ID=23995932

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19910908056 Withdrawn EP0522081A4 (en) 1990-03-30 1991-03-29 Inhibition of disease associated with immunodeficiency virus infection

Country Status (4)

Country Link
EP (1) EP0522081A4 (ja)
JP (1) JPH05506031A (ja)
AU (1) AU7677891A (ja)
WO (1) WO1991015224A1 (ja)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5643872A (en) * 1989-10-23 1997-07-01 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
AU6470590A (en) 1989-10-23 1991-04-26 Smithkline Beecham Corporation Cyclic anti-aggregatory peptides
US5445813A (en) * 1992-11-02 1995-08-29 Bracco International B.V. Stable microbubble suspensions as enhancement agents for ultrasound echography
DE4447484C2 (de) * 1994-04-08 1997-07-17 Deutsches Krebsforsch Mittel zur Hemmung von Apoptose
FR2731355B1 (fr) * 1995-03-08 1997-05-30 Neovacs Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant
WO1996027389A1 (fr) * 1995-03-08 1996-09-12 Neovacs Immunogenes denues de toxicite derivant d'une proteine de regulation retrovirale, anticorps, procede de preparation et compositions pharmaceutiques les renfermant
US6200575B1 (en) 1996-03-07 2001-03-13 Neovacs Non-toxic immunogens derived from a retroviral regulatory protein antibodies preparation process and pharmaceutical compositions comprising them
US8323928B2 (en) 1999-08-12 2012-12-04 Pin Pharma, Inc. Vaccines and immunotherapeutics derived from the human immunodeficiency virus (HIV) transactivator of transcription protein for the treatment and prevention of HIV disease
DE60044303D1 (de) * 1999-08-12 2010-06-10 Inist Inc Nicht-immunsuppresives hiv tat-protein
US7927580B2 (en) 2004-03-16 2011-04-19 Nanirx, Inc. Tat-based immunomodulatory compositions and methods of their discovery and use
CN102405057B (zh) 2009-03-23 2016-05-25 那尼尔科斯治疗公司 用免疫刺激性Hiv Tat衍生物多肽治疗癌症
IT1397569B1 (it) 2009-12-10 2013-01-16 Icgeb Peptidi e loro derivati che inibiscono il rilascio extracellulare della proteina tat di hiv-1 e la replicazione di hiv-1.
WO2015051245A1 (en) 2013-10-04 2015-04-09 Pin Pharma, Inc. Immunostimulatory hiv tat derivative polypeptides for use in cancer treatment

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012461A1 (en) * 1988-06-16 1989-12-28 St. Louis University Antagonists of viral transactivating proteins
WO1992014755A1 (en) * 1991-02-14 1992-09-03 La Jolla Cancer Research Foundation A NOVEL INTEGRIN SPECIFICITY FOR THE HIV Tat PROTEIN

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880779A (en) * 1987-07-31 1989-11-14 Research Corporation Technologies, Inc. Method of prevention or treatment of AIDS by inhibition of human immunodeficiency virus

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989012461A1 (en) * 1988-06-16 1989-12-28 St. Louis University Antagonists of viral transactivating proteins
WO1992014755A1 (en) * 1991-02-14 1992-09-03 La Jolla Cancer Research Foundation A NOVEL INTEGRIN SPECIFICITY FOR THE HIV Tat PROTEIN

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JOURNAL OF VIROLOGY vol. 64, no. 2, February 1990, BALTIMORE pages 962 - 965 BRAKE, D.A. ET AL 'Characterization of murine monoclonal antibodies to the tat protein from human immunodeficiency virus type 1' *
SCIENCE vol. 242, October 1988, LANCASTER, PA US pages 91 - 93 STANLEY E. D'SOUZA ET AL 'Localization of an arg-gly-asp recognition site within an integrin adhesion receptor' *
See also references of WO9115224A1 *
THE JOURNAL OF CELL BIOLOGY vol. 111, no. 3, September 1990, NEW YORK pages 1275 - 1281 BRAKE, D.A. ET AL 'Identification of an arg-gly-asp (RGD) cell adhesion site in human immunodeficiency virus type 1 transactivation protein, tat' *

Also Published As

Publication number Publication date
JPH05506031A (ja) 1993-09-02
EP0522081A1 (en) 1993-01-13
AU7677891A (en) 1991-10-30
WO1991015224A1 (en) 1991-10-17

Similar Documents

Publication Publication Date Title
AU648616B2 (en) Disposable garments
MX9101415A (es) Proteccion femenina desechable
DE69121211T2 (de) Applanationstonometer
HU912526D0 (en) Recombinant marek-type disease virus
ZA924150B (en) Vaccine for human immunodeficiency virus
EP0522081A4 (en) Inhibition of disease associated with immunodeficiency virus infection
ZA90245B (en) Treatment of diseases associated with hiv infections
DZ1706A1 (fr) Vaccin contre le virus de l'hepatite a.
EP0486106A3 (en) Marek's disease virus vaccine
EP0608212A4 (en) PROCESS FOR TREATING VIRAL INFECTIONS.
IL105169A0 (en) Compositions for the treatment of infection and disease caused by hepatitis b virus(hbv)
EP0471407A3 (en) New embodiments of the hiv principal neutralizing determinant
ZA925305B (en) Inhibition of non-CD4 midiated HIV infection.
EP0563323A4 (en) Hiv reverse transcriptase vaccine
EP0442744A3 (en) Treatment of viral disease by glycosides
ZA914435B (en) Treatment of disease
IL102815A (en) Pharmaceutical compositions for the treatment of infection caused by the human immunodeficiency virus
KR930701105A (ko) 안티센스 올리고뉴클레오티드에 의한 헤르페스 비리대 감염의 억제
DE3865694D1 (de) Gegen "cucumber mosaic virus"-infektion resistente pflanzen.
EP0655919A4 (en) TREATMENT OF VIRAL INFECTIONS IN MAN.
GB9006924D0 (en) Prognosis of hepatitis infection
GB2240993B (en) Improvements relating to the handling of hosiery
KR910014244U (ko) 통즈의 다단 잠금 장치
LTIP472A (en) Composition for the treatment of infection and disease caused by hepatit b virus
NZ314730A (en) Use of dideoxycytosine derivatives in the treatment of viral infection

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19920923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19930503

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU NL SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 19940805